This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIntelGenx Technologies（0IL）株式概要ドラッグ・デリバリー企業のインテルジェネックス・テクノロジーズ社は、医薬品市場向けの新規経口薄膜製品の開発と製造に注力している。 詳細0IL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 過去5年間で収益は年間2.4%減少しました。 株式の流動性は非常に低い +2 さらなるリスクすべてのリスクチェックを見る0IL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.141.3k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m6m2016201920222025202620282031Revenue US$736.3kEarnings US$108.1kAdvancedSet Fair ValueView all narrativesFeatured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.675.4% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative57users have followed this narrativeRead narrativeIntelGenx Technologies Corp. 競合他社SynBioticSymbol: DUSE:SBXMarket cap: €15.2mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.6mCantourage GroupSymbol: XTRA:HIGHMarket cap: €74.3mApontis PharmaSymbol: XTRA:APPHMarket cap: €91.6m価格と性能株価の高値、安値、推移の概要IntelGenx Technologies過去の株価現在の株価US$0.1452週高値US$0.2152週安値US$0.061ベータ2.61ヶ月の変化0%3ヶ月変化20.17%1年変化16.26%3年間の変化-57.82%5年間の変化-61.35%IPOからの変化-77.55%最新ニュースお知らせ • Oct 08+ 2 more updatesIntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive OfficerIntelGenx Technologies Corp. announced on October 2, 2024, that Dwight Gorham, Chief Executive Officer, had resigned from his respective position.お知らせ • Aug 15IntelGenx Technologies Corp. announced delayed 10-Q filingOn 08/14/2024, IntelGenx Technologies Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 29ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT) on May 28, 2024. The transaction is a stalking horse bid. The Court approved the agreement of purchase and sale.お知らせ • May 18IntelGenx Technologies Corp. Announces Board ResignationsIntelGenx Technologies Corp. has announced changes to its board of directors as Clemens Mayr, Sahil Kirpekar and Ryan Barrett have resigned from the Board of Directors of the Company, effective immediately.Reported Earnings • May 17First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)First quarter 2024 results: US$0.023 loss per share (further deteriorated from US$0.017 loss in 1Q 2023). Revenue: US$174.0k (up 7.4% from 1Q 2023). Net loss: US$4.03m (loss widened 38% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • Apr 10Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical TrialIntelGenx Technologies Corp. announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study’s Lead Principal Investigator.最新情報をもっと見るRecent updatesお知らせ • Oct 08+ 2 more updatesIntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive OfficerIntelGenx Technologies Corp. announced on October 2, 2024, that Dwight Gorham, Chief Executive Officer, had resigned from his respective position.お知らせ • Aug 15IntelGenx Technologies Corp. announced delayed 10-Q filingOn 08/14/2024, IntelGenx Technologies Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 29ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT) on May 28, 2024. The transaction is a stalking horse bid. The Court approved the agreement of purchase and sale.お知らせ • May 18IntelGenx Technologies Corp. Announces Board ResignationsIntelGenx Technologies Corp. has announced changes to its board of directors as Clemens Mayr, Sahil Kirpekar and Ryan Barrett have resigned from the Board of Directors of the Company, effective immediately.Reported Earnings • May 17First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)First quarter 2024 results: US$0.023 loss per share (further deteriorated from US$0.017 loss in 1Q 2023). Revenue: US$174.0k (up 7.4% from 1Q 2023). Net loss: US$4.03m (loss widened 38% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • Apr 10Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical TrialIntelGenx Technologies Corp. announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study’s Lead Principal Investigator.お知らせ • Apr 05IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDAIntelGenx Corp. announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its resubmitted abbreviated new drug application for Buprenorphine Buccal Film. The CRL includes a request for additional Pharmaceutical Quality information. The FDA confirmed that no additional inspection of IntelGenx’s facility is required at this time. Buprenorphine Buccal Film, which incorporates IntelGenx’s VersaFilm technology in a novel formulation, is a generic version of Belbuca, an opioid that is used to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate. Approved by the FDA in 2015, Belbuca is applied to the oral or buccal mucosa every 12 hours and comes in seven strengths ranging from 0.075 mg to 0.9 mg.お知らせ • Mar 22IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect eight directors to the Company's Board of Directors to serve until the next Annual Meeting of Shareholders of the Company or until their successors are duly elected and qualified; to ratify the appointment of Richter LLP as the Company's Independent Registered Public Accountants for the 2024 fiscal year; to vote on a non-binding, advisory proposal to approve the compensation of the named executive officers and consider and, if deemed advisable, pass an ordinary resolution, approving all unallocated restricted share units and performance share units under the Company's Performance and Restricted Share Unit Plan; and to consider other business matters.New Risk • Mar 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-US$12m). Earnings have declined by 1.4% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$1.0m revenue). Market cap is less than US$100m (€26.3m market cap, or US$28.4m).Reported Earnings • Mar 22Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.057 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$1.04m (up 9.4% from FY 2022). Net loss: US$9.93m (loss narrowed 7.1% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Mar 15IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024IntelGenx Technologies Corp. announced that they will report Q4, 2023 results Pre-Market on Mar 21, 2024お知らせ • Feb 06IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and CatsIntelGenx Corp. announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”). The reliable administration of medications to dogs and cats is a concern for many owners and veterinarians. There are few prescribed medications that dogs and cats will eagerly accept. Forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner(s). Additionally, many owners report that medicating their pet becomes more difficult with each dose, often leading to decreased owner compliance, missed doses and potentially treatment failures. IntelGenx’s VetaFilm®-based fast dissolving oral films (“VetaFilm® FDOFs”) present a new and potentially superior way to medicate companion animals. The research collaboration with UPEI evaluated: (1) the acceptance rate of various VetaFilm® placebo formulations in dogs and cats at first exposure; (2) preference between flavours of VetaFilm® placebo formulations in dogs and cats; (3) changes in acceptance rates over longer periods; and (4), owner perception of ease of administration, acceptance and other behaviors associated with VetaFilm® placebo formulations.お知らせ • Dec 04IntelGenx Technologies Corp. Announces Changes to its Board of DirectorsIntelGenx Technologies Corp. announced the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023. Mr. Stegert and Dr. Rao were the Board designees for atai Life Sciences AG (“atai”) pursuant to the purchaser rights agreement by and between the Company and atai (the “Rights Agreement”). On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the Company’s stockholders, or until their respective successors are duly elected and qualified. Dr. Kirpekar has served as atai’s Chief Business Officer since 2022 and Mr. Barrett has served as atai’s Senior Vice President and General Counsel since August 2020.お知らせ • Nov 15IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's DiseaseIntelGenx Corp. announced that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx's Montelukast VersaFilm for the treatment of Parkinson's Disease. PD is the second most common neurodegenerative disease after Alzheimer's disease, with an estimated 9 million patients globally and 1 million patients in the United States. In the United States it is estimated that 90,000 new patients will be diagnosed with PD every year. No neuroprotective or disease-modifying treatments are currently available. The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa. Evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. Montelukast is a CysLT1 antagonist which decreases neuroinflammation by inhibiting CysLT1. Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer's Disease. The Phase 2 MONTPARK study (CT number 2023-504278-39-00) is a randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast Versa film®? or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.Reported Earnings • Nov 12Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (further deteriorated from US$0.015 loss in 3Q 2022). Revenue: US$318.0k (up 124% from 3Q 2022). Net loss: US$2.76m (loss widened 3.1% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Nov 03IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023IntelGenx Technologies Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$9.2m). Earnings have declined by 2.6% per year over the past 5 years. Revenue is less than US$1m (US$610k revenue). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€27.0m market cap, or US$28.5m).お知らせ • Sep 27Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United StatesGensco® Pharma, in partnership with IntelGenx announced the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx's proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose. RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea. The switch to RizaFilm® is seamless, as it is prescribed the same way as current rizatriptan, but in a Film form. A patient survey indicated that 69% of respondents said they would discuss switching their current migraine therapy to RizaFilm® with their doctor. Patients are encouraged to discuss the benefits of switching to RizaFilm with their healthcare provider.お知らせ • Sep 21IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal FilmIntelGenx Corp. provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application ("ANDA") has been filed with the U.S. Food and Drug Administration ("FDA" or the "Agency") by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC ("Xiromed"). As previously announced, Xiromed received a Complete Response Letter ("CRL") from the FDA in April 2023. In response to the CRL, Xiromed submitted to the FDA an Amendment to the ANDA, requesting priority review. In an Amendment Acknowledgement received from the FDA by Xiromed, the FDA granted priority review with a generic Drug User Fee Act ("GDUFA") goal date for review of the Amendment of March 8, 2024, unless the Agency determines that an inspection is required. Alternatively, if the FDA determines that an inspection is required, the GDUFA goal date is July 8, 2024.お知らせ • Sep 02IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AGIntelGenx Technologies Corp. announced that the company issued 2,220 US units at a price of CAD 1,352.68 ($1,000) per unit for the gross proceeds of CAD 3,002,950 on August 31, 2023. The company may issue additional US units for the gross proceeds of CAD 7,020,410 and Canadian units for the gross proceeds of CAD 1,400,000. The tranche included participation from returning investor, ATAI Life Sciences AG. In addition, the investor committed to subscribe for an additional 750 US Units for additional aggregate proceeds of CAD 1,014,510 ($750,000), on the same terms, subject to the company obtaining the shareholder approvals. The transaction is expected to close on or before October 13, 2023. All securities issued in connection with the offering, including shares issuable pursuant to the conversion of the notes or exercise of the warrants, are subject to a 6-month hold period, during which time trading in the securities is restricted in accordance with applicable securities laws.お知らせ • Aug 23Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseIntelGenx Corp. announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a clinical trial in patients with mild to moderate Alzheimer's Disease. The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value to p<0.1 will provide a basis for determining the extent to which effect sizes of 0.6 or greater are statistically significant. GlobalData recently reported that the AD market is expected to reach $13.7 billion in 2030 across the eight major markets (U.S., France, Germany, Italy, Spain, U.K., Japan, and China), representing a compound annual growth rate of 20.0% from $2.2 billion in 2020. The expansion is primarily attributed to the significant unmet needs posed by AD, combined with the introduction of new therapies, including the recently approved Leqembi and donanemab, which is expected to be approved by year-end. Montelukast is a leukotriene receptor antagonist that was approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. IntelGenx is working to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. IntelGenx's proprietary VersaFilm® technology is especially suited for special needs patient populations, and the Montelukast VersaFilm product offers many distinct advantages over tablets for AD and Parkinson's Disease patients, including the avoidance and minimization of first- pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance. In Phase 1 studies, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022)Second quarter 2023 results: US$0.016 loss per share. Revenue: US$133.0k (down 67% from 2Q 2022). Net loss: US$2.86m (loss widened 11% from 2Q 2022).お知らせ • Aug 08IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023IntelGenx Technologies Corp. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023お知らせ • Aug 02Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseIntelGenx Corp. announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a ("BUENA") clinical trial in patients with mild to moderate Alzheimer's Disease ("AD"). The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter ("NOL") from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value (which determines whether a drug effect exists) to p $13.7 billion in 2030 across the eight major markets (U.S., France, Germany, Italy, Spain, U.K., Japan, and China), representing a compound annual growth rate of 20.0% from $2.2 billion in 2020. The expansion is primarily attributed to the significant unmet needs posed by AD, combined with the introduction of new therapies, including the recently approved Leqembi and donanemab, which is expected to be approved by year-end.お知らせ • Jul 26Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's DiseaseIntelGenx Corp. announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the "Study") to investigate the use of IntelGenx's Montelukast VersaFilm®? for the treatment of Parkinson's Disease ("PD"). The Study will be conducted at the Karolinska University Hospital under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who will serve as the Study's Principal Investigator. Dr. Svenningsson - a Professor of Clinical Neuroscience who investigates the pathogenic mechanisms of PD - previously conducted a clinical study utilizing the tablet form of Montelukast for the treatment of PD, where 2 tablets of 10 mg Montelukast were administered twice daily, for a total daily dose of 40 mg.Board Change • Jul 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Monika Trzcinska was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of DirectorsIntelGenx Technologies Corp. announced the resignation of Mr. J. Bernard (Bernie) Boudreau from the Board of Directors of the Company effective July 21, 2023. Mr. Boudreau was a Director of the Company since 2006 and the Vice Chairman since 2014. He was also the Chair of the Corporate Governance and Nomination Committee.Reported Earnings • May 14First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022)First quarter 2023 results: US$0.017 loss per share (in line with 1Q 2022). Revenue: US$162.0k (down 32% from 1Q 2022). Net loss: US$2.92m (loss widened 8.9% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • May 05IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023IntelGenx Technologies Corp. announced that they will report Q1, 2023 results on May 11, 2023Reported Earnings • Mar 30Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021)Full year 2022 results: US$0.065 loss per share. Revenue: US$950.0k (down 38% from FY 2021). Net loss: US$10.7m (loss widened 15% from FY 2021).Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)Third quarter 2022 results: US$0.015 loss per share (further deteriorated from US$0.013 loss in 3Q 2021). Revenue: US$142.0k (down 76% from 3Q 2021). Net loss: US$2.68m (loss widened 34% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)Third quarter 2022 results: US$0.015 loss per share (further deteriorated from US$0.013 loss in 3Q 2021). Revenue: US$142.0k (down 76% from 3Q 2021). Net loss: US$2.68m (loss widened 34% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 15Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021)Second quarter 2022 results: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021). Revenue: US$398.0k (up 146% from 2Q 2021). Net loss: US$2.58m (loss widened 18% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • May 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mark Nawacki was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$593.0k (up 16% from 3Q 2020). Net loss: US$2.00m (loss widened 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$162.0k (up 286% from 2Q 2020). Net loss: US$2.19m (loss widened 33% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • May 16First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$286.0k (up 42% from 1Q 2020). Net loss: US$2.26m (loss narrowed 8.0% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 27Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.54m (up 108% from FY 2019). Net loss: US$7.04m (loss narrowed 34% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 09New 90-day high: €0.30The company is up 156% from its price of €0.12 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €0.22The company is up 56% from its price of €0.14 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: US$0.015 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$510.0k (up US$449.0k from 3Q 2019). Net loss: US$1.66m (loss narrowed 41% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.株主還元0ILDE PharmaceuticalsDE 市場7D0%0.2%-0.02%1Y16.3%10.6%0.1%株主還元を見る業界別リターン: 0IL過去 1 年間で10.6 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: 0IL過去 1 年間で0.1 % の収益を上げたGerman市場を上回りました。価格変動Is 0IL's price volatile compared to industry and market?0IL volatility0IL Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.4%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.6%安定した株価: 0ILの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の0ILのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003n/aDwight Gorhamwww.intelgenx.comドラッグデリバリー企業のインテルジェネックス・テクノロジーズ・コーポレーション（IntelGenx Technologies Corp.片頭痛治療用リザトリプタン経口フィルム製品INT0008/2008、成人用INT0046/2018およびINT0055/2021、勃起不全治療用経口フィルム製品INT0007/2006、アルツハイマー病およびパーキンソン病治療用モンテルカスト含有経口フィルムINT0043/2015を提供している；INT0027/2011：オピオイド依存症治療薬、INT0010/2006：化学療法中のがん患者における神経障害性疼痛および吐き気治療薬、INT0036/2013：統合失調症または双極性1型障害治療用経口フィルム製剤、INT0048/2020：動物用医薬品。また、疼痛治療薬INT0039/2013、抵抗性うつ病治療薬INT0053/2020も開発している。同社はTilray, Inc.とライセンス・開発・供給契約を、Cynapsus Therapeutics Inc.と開発契約を結んでいる。インテルジェネックス・テクノロジーズ社は2003年に設立され、カナダのモントリオールに本社を置いている。もっと見るIntelGenx Technologies Corp. 基礎のまとめIntelGenx Technologies の収益と売上を時価総額と比較するとどうか。0IL 基礎統計学時価総額€26.46m収益（TTM）-€10.01m売上高(TTM)€953.47k27.8xP/Sレシオ-2.6xPER（株価収益率0IL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0IL 損益計算書（TTM）収益US$1.05m売上原価US$1.75m売上総利益-US$694.00kその他の費用US$10.34m収益-US$11.03m直近の収益報告Mar 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.063グロス・マージン-66.03%純利益率-1,049.48%有利子負債／自己資本比率-103.7%0IL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/14 03:40終値2024/05/17 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IntelGenx Technologies Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Benjamin HaynorAegis Capital CorporationChristian OrqueraFirst Berlin Equity Research GmbHSwayampakula RamakanthH.C. Wainwright & Co.3 その他のアナリストを表示
Featured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.675.4% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative57users have followed this narrativeRead narrative
お知らせ • Oct 08+ 2 more updatesIntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive OfficerIntelGenx Technologies Corp. announced on October 2, 2024, that Dwight Gorham, Chief Executive Officer, had resigned from his respective position.
お知らせ • Aug 15IntelGenx Technologies Corp. announced delayed 10-Q filingOn 08/14/2024, IntelGenx Technologies Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 29ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT) on May 28, 2024. The transaction is a stalking horse bid. The Court approved the agreement of purchase and sale.
お知らせ • May 18IntelGenx Technologies Corp. Announces Board ResignationsIntelGenx Technologies Corp. has announced changes to its board of directors as Clemens Mayr, Sahil Kirpekar and Ryan Barrett have resigned from the Board of Directors of the Company, effective immediately.
Reported Earnings • May 17First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)First quarter 2024 results: US$0.023 loss per share (further deteriorated from US$0.017 loss in 1Q 2023). Revenue: US$174.0k (up 7.4% from 1Q 2023). Net loss: US$4.03m (loss widened 38% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • Apr 10Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical TrialIntelGenx Technologies Corp. announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study’s Lead Principal Investigator.
お知らせ • Oct 08+ 2 more updatesIntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive OfficerIntelGenx Technologies Corp. announced on October 2, 2024, that Dwight Gorham, Chief Executive Officer, had resigned from his respective position.
お知らせ • Aug 15IntelGenx Technologies Corp. announced delayed 10-Q filingOn 08/14/2024, IntelGenx Technologies Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 29ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT) on May 28, 2024. The transaction is a stalking horse bid. The Court approved the agreement of purchase and sale.
お知らせ • May 18IntelGenx Technologies Corp. Announces Board ResignationsIntelGenx Technologies Corp. has announced changes to its board of directors as Clemens Mayr, Sahil Kirpekar and Ryan Barrett have resigned from the Board of Directors of the Company, effective immediately.
Reported Earnings • May 17First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)First quarter 2024 results: US$0.023 loss per share (further deteriorated from US$0.017 loss in 1Q 2023). Revenue: US$174.0k (up 7.4% from 1Q 2023). Net loss: US$4.03m (loss widened 38% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • Apr 10Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical TrialIntelGenx Technologies Corp. announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study’s Lead Principal Investigator.
お知らせ • Apr 05IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDAIntelGenx Corp. announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its resubmitted abbreviated new drug application for Buprenorphine Buccal Film. The CRL includes a request for additional Pharmaceutical Quality information. The FDA confirmed that no additional inspection of IntelGenx’s facility is required at this time. Buprenorphine Buccal Film, which incorporates IntelGenx’s VersaFilm technology in a novel formulation, is a generic version of Belbuca, an opioid that is used to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate. Approved by the FDA in 2015, Belbuca is applied to the oral or buccal mucosa every 12 hours and comes in seven strengths ranging from 0.075 mg to 0.9 mg.
お知らせ • Mar 22IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect eight directors to the Company's Board of Directors to serve until the next Annual Meeting of Shareholders of the Company or until their successors are duly elected and qualified; to ratify the appointment of Richter LLP as the Company's Independent Registered Public Accountants for the 2024 fiscal year; to vote on a non-binding, advisory proposal to approve the compensation of the named executive officers and consider and, if deemed advisable, pass an ordinary resolution, approving all unallocated restricted share units and performance share units under the Company's Performance and Restricted Share Unit Plan; and to consider other business matters.
New Risk • Mar 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-US$12m). Earnings have declined by 1.4% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$1.0m revenue). Market cap is less than US$100m (€26.3m market cap, or US$28.4m).
Reported Earnings • Mar 22Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.057 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$1.04m (up 9.4% from FY 2022). Net loss: US$9.93m (loss narrowed 7.1% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Mar 15IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024IntelGenx Technologies Corp. announced that they will report Q4, 2023 results Pre-Market on Mar 21, 2024
お知らせ • Feb 06IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and CatsIntelGenx Corp. announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”). The reliable administration of medications to dogs and cats is a concern for many owners and veterinarians. There are few prescribed medications that dogs and cats will eagerly accept. Forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner(s). Additionally, many owners report that medicating their pet becomes more difficult with each dose, often leading to decreased owner compliance, missed doses and potentially treatment failures. IntelGenx’s VetaFilm®-based fast dissolving oral films (“VetaFilm® FDOFs”) present a new and potentially superior way to medicate companion animals. The research collaboration with UPEI evaluated: (1) the acceptance rate of various VetaFilm® placebo formulations in dogs and cats at first exposure; (2) preference between flavours of VetaFilm® placebo formulations in dogs and cats; (3) changes in acceptance rates over longer periods; and (4), owner perception of ease of administration, acceptance and other behaviors associated with VetaFilm® placebo formulations.
お知らせ • Dec 04IntelGenx Technologies Corp. Announces Changes to its Board of DirectorsIntelGenx Technologies Corp. announced the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023. Mr. Stegert and Dr. Rao were the Board designees for atai Life Sciences AG (“atai”) pursuant to the purchaser rights agreement by and between the Company and atai (the “Rights Agreement”). On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the Company’s stockholders, or until their respective successors are duly elected and qualified. Dr. Kirpekar has served as atai’s Chief Business Officer since 2022 and Mr. Barrett has served as atai’s Senior Vice President and General Counsel since August 2020.
お知らせ • Nov 15IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's DiseaseIntelGenx Corp. announced that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx's Montelukast VersaFilm for the treatment of Parkinson's Disease. PD is the second most common neurodegenerative disease after Alzheimer's disease, with an estimated 9 million patients globally and 1 million patients in the United States. In the United States it is estimated that 90,000 new patients will be diagnosed with PD every year. No neuroprotective or disease-modifying treatments are currently available. The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa. Evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. Montelukast is a CysLT1 antagonist which decreases neuroinflammation by inhibiting CysLT1. Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer's Disease. The Phase 2 MONTPARK study (CT number 2023-504278-39-00) is a randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast Versa film®? or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.
Reported Earnings • Nov 12Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (further deteriorated from US$0.015 loss in 3Q 2022). Revenue: US$318.0k (up 124% from 3Q 2022). Net loss: US$2.76m (loss widened 3.1% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Nov 03IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023IntelGenx Technologies Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$9.2m). Earnings have declined by 2.6% per year over the past 5 years. Revenue is less than US$1m (US$610k revenue). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€27.0m market cap, or US$28.5m).
お知らせ • Sep 27Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United StatesGensco® Pharma, in partnership with IntelGenx announced the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx's proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose. RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea. The switch to RizaFilm® is seamless, as it is prescribed the same way as current rizatriptan, but in a Film form. A patient survey indicated that 69% of respondents said they would discuss switching their current migraine therapy to RizaFilm® with their doctor. Patients are encouraged to discuss the benefits of switching to RizaFilm with their healthcare provider.
お知らせ • Sep 21IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal FilmIntelGenx Corp. provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application ("ANDA") has been filed with the U.S. Food and Drug Administration ("FDA" or the "Agency") by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC ("Xiromed"). As previously announced, Xiromed received a Complete Response Letter ("CRL") from the FDA in April 2023. In response to the CRL, Xiromed submitted to the FDA an Amendment to the ANDA, requesting priority review. In an Amendment Acknowledgement received from the FDA by Xiromed, the FDA granted priority review with a generic Drug User Fee Act ("GDUFA") goal date for review of the Amendment of March 8, 2024, unless the Agency determines that an inspection is required. Alternatively, if the FDA determines that an inspection is required, the GDUFA goal date is July 8, 2024.
お知らせ • Sep 02IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AGIntelGenx Technologies Corp. announced that the company issued 2,220 US units at a price of CAD 1,352.68 ($1,000) per unit for the gross proceeds of CAD 3,002,950 on August 31, 2023. The company may issue additional US units for the gross proceeds of CAD 7,020,410 and Canadian units for the gross proceeds of CAD 1,400,000. The tranche included participation from returning investor, ATAI Life Sciences AG. In addition, the investor committed to subscribe for an additional 750 US Units for additional aggregate proceeds of CAD 1,014,510 ($750,000), on the same terms, subject to the company obtaining the shareholder approvals. The transaction is expected to close on or before October 13, 2023. All securities issued in connection with the offering, including shares issuable pursuant to the conversion of the notes or exercise of the warrants, are subject to a 6-month hold period, during which time trading in the securities is restricted in accordance with applicable securities laws.
お知らせ • Aug 23Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseIntelGenx Corp. announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a clinical trial in patients with mild to moderate Alzheimer's Disease. The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value to p<0.1 will provide a basis for determining the extent to which effect sizes of 0.6 or greater are statistically significant. GlobalData recently reported that the AD market is expected to reach $13.7 billion in 2030 across the eight major markets (U.S., France, Germany, Italy, Spain, U.K., Japan, and China), representing a compound annual growth rate of 20.0% from $2.2 billion in 2020. The expansion is primarily attributed to the significant unmet needs posed by AD, combined with the introduction of new therapies, including the recently approved Leqembi and donanemab, which is expected to be approved by year-end. Montelukast is a leukotriene receptor antagonist that was approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. IntelGenx is working to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. IntelGenx's proprietary VersaFilm® technology is especially suited for special needs patient populations, and the Montelukast VersaFilm product offers many distinct advantages over tablets for AD and Parkinson's Disease patients, including the avoidance and minimization of first- pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance. In Phase 1 studies, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022)Second quarter 2023 results: US$0.016 loss per share. Revenue: US$133.0k (down 67% from 2Q 2022). Net loss: US$2.86m (loss widened 11% from 2Q 2022).
お知らせ • Aug 08IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023IntelGenx Technologies Corp. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
お知らせ • Aug 02Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseIntelGenx Corp. announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a ("BUENA") clinical trial in patients with mild to moderate Alzheimer's Disease ("AD"). The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter ("NOL") from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value (which determines whether a drug effect exists) to p $13.7 billion in 2030 across the eight major markets (U.S., France, Germany, Italy, Spain, U.K., Japan, and China), representing a compound annual growth rate of 20.0% from $2.2 billion in 2020. The expansion is primarily attributed to the significant unmet needs posed by AD, combined with the introduction of new therapies, including the recently approved Leqembi and donanemab, which is expected to be approved by year-end.
お知らせ • Jul 26Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's DiseaseIntelGenx Corp. announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the "Study") to investigate the use of IntelGenx's Montelukast VersaFilm®? for the treatment of Parkinson's Disease ("PD"). The Study will be conducted at the Karolinska University Hospital under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who will serve as the Study's Principal Investigator. Dr. Svenningsson - a Professor of Clinical Neuroscience who investigates the pathogenic mechanisms of PD - previously conducted a clinical study utilizing the tablet form of Montelukast for the treatment of PD, where 2 tablets of 10 mg Montelukast were administered twice daily, for a total daily dose of 40 mg.
Board Change • Jul 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Monika Trzcinska was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of DirectorsIntelGenx Technologies Corp. announced the resignation of Mr. J. Bernard (Bernie) Boudreau from the Board of Directors of the Company effective July 21, 2023. Mr. Boudreau was a Director of the Company since 2006 and the Vice Chairman since 2014. He was also the Chair of the Corporate Governance and Nomination Committee.
Reported Earnings • May 14First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022)First quarter 2023 results: US$0.017 loss per share (in line with 1Q 2022). Revenue: US$162.0k (down 32% from 1Q 2022). Net loss: US$2.92m (loss widened 8.9% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • May 05IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023IntelGenx Technologies Corp. announced that they will report Q1, 2023 results on May 11, 2023
Reported Earnings • Mar 30Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021)Full year 2022 results: US$0.065 loss per share. Revenue: US$950.0k (down 38% from FY 2021). Net loss: US$10.7m (loss widened 15% from FY 2021).
Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)Third quarter 2022 results: US$0.015 loss per share (further deteriorated from US$0.013 loss in 3Q 2021). Revenue: US$142.0k (down 76% from 3Q 2021). Net loss: US$2.68m (loss widened 34% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)Third quarter 2022 results: US$0.015 loss per share (further deteriorated from US$0.013 loss in 3Q 2021). Revenue: US$142.0k (down 76% from 3Q 2021). Net loss: US$2.68m (loss widened 34% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 15Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021)Second quarter 2022 results: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021). Revenue: US$398.0k (up 146% from 2Q 2021). Net loss: US$2.58m (loss widened 18% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • May 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mark Nawacki was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$593.0k (up 16% from 3Q 2020). Net loss: US$2.00m (loss widened 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$162.0k (up 286% from 2Q 2020). Net loss: US$2.19m (loss widened 33% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • May 16First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$286.0k (up 42% from 1Q 2020). Net loss: US$2.26m (loss narrowed 8.0% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 27Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.54m (up 108% from FY 2019). Net loss: US$7.04m (loss narrowed 34% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 09New 90-day high: €0.30The company is up 156% from its price of €0.12 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €0.22The company is up 56% from its price of €0.14 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: US$0.015 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$510.0k (up US$449.0k from 3Q 2019). Net loss: US$1.66m (loss narrowed 41% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
